4-甲基-N-苯基-嘧啶-2-胺 | 53112-26-8

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲基-N-苯基-嘧啶-2-胺
• 英文名称: 4-methyl-N-phenylpyrimidin-2-amine
• 英文别名: (4-methyl-pyrimidin-2-yl)-phenyl-amine；(4-Methyl-pyrimidin-2-yl)-phenyl-amin；4-Methyl-2-phenylamino-pyrimidin；2-Anilino-4-methyl-pyrimidin
• CAS: 53112-26-8
• 化学式: C₁₁H₁₁N₃
• 分子量: 185.228
• InChiKey: QYVJAFZWBTUAJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-甲基-N-苯基-嘧啶-2-胺 、 6-苯基-咪唑并[2,1-b]噻唑-5-甲醛 生成 N-phenyl-4-[(E)-2-(6-phenylimidazo[2,1-b][1,3]thiazol-5-yl)vinyl]pyrimidin-2-amine
  参考文献：
  名称：

  Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable

  摘要：

  Tie-2 is a receptor tyrosine kinase which is involved in angiogenesis and thereby growth of human tumours. The discovery and SAR of a novel class of imidazole-vinyl-pyrimidine kinase inhibitors, which inhibit Tie-2 in vitro is reported. Their synthesis was carried out by condensation of imidazole aldehydes with methyl pyrimidines. These compounds are lead-like, with low molecular weight, good physical properties and oral bioavailability. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.106
• 作为产物：
  描述：

  2-氯-4-甲基嘧啶 在 potassium carbonate 作用下， 生成 4-甲基-N-苯基-嘧啶-2-胺
  参考文献：
  名称：

  Matsukawa; Sirakawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1951, vol. 71, p. 1313

  摘要：

  DOI：

文献信息

• METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150099875A1

  公开（公告）日：2015-04-09

  The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.

  本发明涉及通过顺序亲核芳香取代法合成2,4-二取代嘧啶的新颖区域选择性合成。
• JNK modulators
  申请人：Dunn James Patrick

  公开号：US20080146565A1

  公开（公告）日：2008-06-19

  Compounds of formula I modulate JNK: wherein the variables are as defined herein.

  式I的化合物调节JNK： 其中变量的定义如本文所述。
• Pyrimidine Derivatives
  申请人：Klebl Bert

  公开号：US20080187575A1

  公开（公告）日：2008-08-07

  The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. Furthermore, the present invention relates to pharmaceutical compositions containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders.

  本发明涉及嘧啶衍生物，其合成方法，以及所述嘧啶衍生物作为药用活性剂的用途，特别是用于预防和/或治疗细胞增殖紊乱、癌症、白血病、勃起功能障碍、心血管疾病和紊乱、炎症性疾病、移植排斥、免疫性疾病、神经免疫性疾病、自身免疫性疾病、感染性疾病包括机会性感染、朊病和/或神经退行性疾病。此外，本发明涉及含有至少一种嘧啶衍生物和/或其药用可接受盐作为活性成分的药物组合物，以及用于预防和/或治疗上述疾病和紊乱的方法。
• [EN] PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS<br/>[FR] COMPOSÉS PYRIDINAMINE-PYRIDONE ET PYRIMIDINAMINE-PYRIDONE
  申请人：SPRINT BIOSCIENCE AB

  公开号：WO2019038389A1

  公开（公告）日：2019-02-28

  The invention provides novel pyridinamine-pyridone and pyrimidinamine- pyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections; (I) wherein R1, R2, R3 and Z are as defined in the specification.

  该发明提供了式（I）的新型吡啶胺基-吡啶酮和嘧啶胺基-吡啶酮化合物，包含这些化合物的药物组合物，以及使用这些化合物治疗癌症、2型糖尿病、炎症性疾病、神经退行性疾病、心血管疾病、自身免疫疾病和病毒感染等疾病的方法；其中R1、R2、R3和Z如规范中所定义。
• CuOTf-Catalyzed Selective Generation of 2-Aminopyrimidines from Carbodiimides and Diaryliodonium Salts by a Triple C(sp³)−H Functionalization
  作者：Yue Chi、Haihan Yan、Wen-Xiong Zhang、Zhenfeng Xi

  DOI：10.1002/chem.201604739

  日期：2017.1.18

  The selective C(sp3)−H bond functionalization is an ideal and atom‐economical method in organic synthesis. In this work, 2‐aminopyrimidines are generated from a Cu‐catalyzed reaction between carbodiimides and diaryliodonium salts, by cleavage of four C(sp3)−H, one C−N, and one C=N bonds in the carbodiimides. It is the first triple C(sp3)−H bond functionalization neighboring a C=N bond. The selective

  选择性的C（sp 3）-H键官能化是有机合成中一种理想且原子经济的方法。在这项工作中，通过在碳二亚胺中切割四个C（sp 3）-H，一个C-N和一个C = N键，在碳催化的碳二亚胺和二芳基碘鎓盐之间的反应中生成了2-氨基嘧啶。它是与C = N键相邻的第一个三元C（sp 3）-H键官能化。2-氨基嘧啶的选择性合成受二芳基碘鎓盐的量控制。通过检测重要的中间体和进行DFT计算，可以很好地阐明涉及CN形成/ 1,5-H移位/ 1,7-H移位/ 6π-电环闭环/芳构化的新机制。